Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression:: A novel antiarrhythmic mechanism

被引:9
作者
Drvota, V [1 ]
Blange, I [1 ]
Häggblad, J [1 ]
Sylvén, C [1 ]
机构
[1] Huddinge Univ Hosp, Dept Cardiol, Karolinska Inst, S-14186 Huddinge, Sweden
关键词
desethylamiodarone; almokalant; thyroid hormone; cardiac repolarization; monophasic action potentials; guinea pig;
D O I
10.1097/00005344-199810000-00020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Desethylamiodarone (DEA) is the major metabolite of amiodarone and has similar electrophysiologic effects with prolongation of the repolarization that is reversed by thyroid hormone (T-3) Some of the electrophysiologic effects are probably due to antagonism of T-3 at the receptor level. Such effects of T-3 are mediated by modulation of gene transcription. The aim of this study was to investigate whether cycloheximide (Cy), an inhibitor of protein synthesis, and actinomycin D (ActD), a RNA-synthesis inhibitor, block DEA-induced prolongation of the repolarization and whether DEA takes part in the autoregulation of the nuclear thyroid hormone-receptor subtypes (ThR). Corrected monophasic action potentials (MAP,) and QT(c) were measured in Langendorff-perfused guinea pig hearts for 1 h. The hearts were continuously perfused with (a) vehicle. (b) 7.5 mu M Cy, (c) 5 mu M DEA, (d) 5 mu M DEA + 7.5 mu M Cy, (e) 1 mu M T-3 (f) 5 mu M DEA + 1 mu M T-3, (g) 1.5 mu M ActD, and (h) ActD + DEA. A potassium channel blocker with class III antiarrhythmic effects, 0.5 mu M almokalant, was used as a control, separately and together with Cy. Western blot analysis for the ThR subtypes alpha, beta(1), and beta(2) was performed on vehicle- and DEA-treated hearts. DEA increased MAPc by 19% (p < 0.0005) and QT(c) by 18% (p < 0.0005). There was no effect on MAP or QT(c) when Cy, ActD, or T3 was added with DEA. Almokalant increased MAP, by 14% (p < 0.005) and QT(c) by 13% (p < 0.0005). When Cy was present, almokalant still induced a similar prolongation of MAP, by 14% (p < 0.005) and QT(c) by 17% (p < 0.0005). Western blot analysis revealed no change in the expression of the ThR protein. In conclusion, the prolongation of the cardiac repolarization by DEA, but not almokalant, can be totally blocked by Cy and ActD. This indicates that the class III action of DEA is at least in part dependent on transcription rather than a direct effect on cell-membrane channels or receptors. The action of DEA could be reversed by T-3, indicating an antagonism between DEA and T3 These results suggest a new antiarrhythmic mechanism dependent on gene expression.
引用
收藏
页码:654 / 661
页数:8
相关论文
共 39 条
[1]   DESETHYLAMIODARONE IS A NONCOMPETITIVE INHIBITOR OF THE BINDING OF THYROID-HORMONE TO THE THYROID-HORMONE BETA(1)-RECEPTOR PROTEIN [J].
BAKKER, O ;
VANBEEREN, HC ;
WIERSINGA, WM .
ENDOCRINOLOGY, 1994, 134 (04) :1665-1670
[2]   EFFECTS OF CHRONIC AMIODARONE TREATMENT ON HUMAN MYOCARDIAL BETA ADRENOCEPTOR DENSITY AND ADENYLATE-CYCLASE RESPONSE [J].
BJORNERHEIM, R ;
FROYSAKER, T ;
HANSSON, V .
CARDIOVASCULAR RESEARCH, 1991, 25 (06) :503-509
[3]   MODELS FOR THE BINDING OF AMIODARONE TO THE THYROID-HORMONE RECEPTOR [J].
CHALMERS, DK ;
MUNRO, SLA ;
ISKANDER, MN ;
CRAIK, DJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1992, 6 (01) :19-31
[4]   DOWN-REGULATION OF THYROID-HORMONE RECEPTOR SUBTYPE MESSENGER-RNA LEVELS BY AMIODARONE DURING CATECHOLAMINE STRESS IN-VITRO [J].
DRVOTA, V ;
BRONNEGARD, M ;
HAGGBLAD, J ;
BARKHEM, T ;
SYLVEN, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 211 (03) :991-996
[5]   AMIODARONE IS A DOSE-DEPENDENT NONCOMPETITIVE AND COMPETITIVE INHIBITOR OF T3 BINDING TO THYROID-HORMONE RECEPTOR SUBTYPE BETA-1, WHEREAS DISOPYRAMIDE, LIGNOCAINE, PROPAFENONE, METOPROLOL, DL-SOTALOL, AND VERAPAMIL HAVE NO INHIBITORY EFFECT [J].
DRVOTA, V ;
CARLSSON, B ;
HAGGBLAD, J ;
SYLVEN, C .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (02) :222-226
[6]  
DUKER G D, 1990, Journal of Molecular and Cellular Cardiology, V22, pS82, DOI 10.1016/0022-2828(90)91772-Y
[7]   EVENTS IN THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL (CAST) - MORTALITY IN THE ENTIRE POPULATION ENROLLED [J].
EPSTEIN, AE ;
BIGGER, JT ;
WYSE, DG ;
ROMHILT, DW ;
REYNOLDSHAERTLE, RA ;
HALLSTROM, AP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (01) :14-19
[8]  
FOLLMER CH, 1987, J PHARMACOL EXP THER, V243, P187
[9]   REGULATION OF ALPHA-MYOSIN AND BETA-MYOSIN HEAVY-CHAIN MESSENGER-RNAS IN THE RAT MYOCARDIUM BY AMIODARONE AND BY THYROID STATUS [J].
FRANKLYN, JA ;
GREEN, NK ;
GAMMAGE, MD ;
AHLQUIST, JAO ;
SHEPPARD, MC .
CLINICAL SCIENCE, 1989, 76 (05) :463-467
[10]   PHARMACOLOGY AND PHARMACOKINETICS OF AMIODARONE [J].
FREEDMAN, MD ;
SOMBERG, JC .
JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (11) :1061-1069